NO20070061L - 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav - Google Patents

3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav

Info

Publication number
NO20070061L
NO20070061L NO20070061A NO20070061A NO20070061L NO 20070061 L NO20070061 L NO 20070061L NO 20070061 A NO20070061 A NO 20070061A NO 20070061 A NO20070061 A NO 20070061A NO 20070061 L NO20070061 L NO 20070061L
Authority
NO
Norway
Prior art keywords
ribofuranosylthiazolo
beta
compounds
nucleosides
pyridimine
Prior art date
Application number
NO20070061A
Other languages
English (en)
Norwegian (no)
Inventor
David Louis Clark
Stephen E Webber
Devron R Averett
Erik J Rueden
Joseph R Lennox
Alan X Xiang
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34959084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070061(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of NO20070061L publication Critical patent/NO20070061L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO20070061A 2004-06-07 2007-01-04 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav NO20070061L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/018011 WO2005121162A1 (en) 2004-06-07 2004-06-07 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF

Publications (1)

Publication Number Publication Date
NO20070061L true NO20070061L (no) 2007-03-05

Family

ID=34959084

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070061A NO20070061L (no) 2004-06-07 2007-01-04 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav

Country Status (21)

Country Link
US (1) US20080070852A1 (zh)
EP (1) EP1758916B1 (zh)
JP (1) JP4856638B2 (zh)
CN (1) CN1964985A (zh)
AR (1) AR049203A1 (zh)
AU (1) AU2004320625B2 (zh)
BR (1) BRPI0418887A (zh)
CA (1) CA2566541C (zh)
ES (1) ES2399891T3 (zh)
IL (1) IL179529A0 (zh)
IS (1) IS8575A (zh)
MX (1) MXPA06014182A (zh)
NO (1) NO20070061L (zh)
PA (1) PA8635901A1 (zh)
PE (1) PE20060455A1 (zh)
RU (1) RU2006146204A (zh)
SV (1) SV2006002135A (zh)
TN (1) TNSN06403A1 (zh)
TW (1) TW200612969A (zh)
UY (1) UY28943A1 (zh)
WO (1) WO2005121162A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009486D0 (en) * 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
WO2006066080A1 (en) * 2004-12-17 2006-06-22 Anadys Pharmaceuticals, Inc. 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
BRPI0710878A2 (pt) 2006-04-11 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
AR061024A1 (es) * 2006-05-22 2008-07-30 Novartis Ag Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
PL2014771T3 (pl) * 2007-06-25 2015-05-29 Anadys Pharmaceuticals Inc Ciągły proces hydrolizy enzymatycznej
EP2019113A1 (en) * 2007-07-26 2009-01-28 Anadys Pharmaceuticals, Inc. New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CA2773773C (en) * 2009-09-21 2019-04-23 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
CN102153548B (zh) * 2011-02-24 2012-11-28 河北大学 一种含有噻唑(嗪)烷酮环的类核苷衍生物及其制备方法和其在药物制剂中的应用
TW202345800A (zh) * 2022-04-06 2023-12-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
CN116589606B (zh) * 2022-12-01 2024-05-28 中国药科大学 一种丁酰化酵母葡聚糖及其制备方法、应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041426A (en) * 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
KR100718371B1 (ko) * 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 3-β-D-리보푸라노실티아졸로[4,5-d]피리디민누클레오시드 및 이의 용도

Also Published As

Publication number Publication date
WO2005121162A1 (en) 2005-12-22
AR049203A1 (es) 2006-07-05
PA8635901A1 (es) 2006-07-03
AU2004320625B2 (en) 2009-08-27
US20080070852A1 (en) 2008-03-20
SV2006002135A (es) 2006-05-08
MXPA06014182A (es) 2007-06-25
IS8575A (is) 2006-12-05
EP1758916B1 (en) 2012-11-21
RU2006146204A (ru) 2008-07-20
CA2566541C (en) 2012-10-09
CA2566541A1 (en) 2005-12-22
EP1758916A1 (en) 2007-03-07
CN1964985A (zh) 2007-05-16
ES2399891T3 (es) 2013-04-04
PE20060455A1 (es) 2006-06-19
JP2008501792A (ja) 2008-01-24
IL179529A0 (en) 2007-05-15
TNSN06403A1 (en) 2008-02-22
JP4856638B2 (ja) 2012-01-18
TW200612969A (en) 2006-05-01
UY28943A1 (es) 2006-01-31
BRPI0418887A (pt) 2007-10-30
AU2004320625A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
NO20070061L (no) 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
YU45204A (sh) 3-BETA-D-RIBOFURANOZILTIAZOLO/4,5-d/ PIRIMIDINSKI NUKLEOZIDII NJIHOVA UPOTREBA
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2006004741A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2006004684A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
TW200611695A (en) Pyrrolopyridine derivatives
NO20063787L (no) Terapeutiske preparater
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
NO20064974L (no) terapeutiske midler
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2002079149A3 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU2003260436A1 (en) Pyrimidine compounds
ATE451350T1 (de) Arylalkylsulfonamide als therapeutische mittel zur behandlung von knochenleiden
UA83142C2 (en) 3-aminocyclopentane carboxyamidine as modulators of chemokine receptors
UA91697C2 (en) 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
DOP2005000261A (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4,5-d] pirrimidin-2-ona 3,5-disustituida y 3,5,7-trisustituida y profarmacos de los mismo
IL160604A0 (en) C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application